Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III trial of MN-166 (ibudilast) in progressive multiple sclerosis

Trial Profile

A Phase III trial of MN-166 (ibudilast) in progressive multiple sclerosis

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 13 May 2021 According to a MediciNova media release, the company is engaged in a process with potential partners regarding MN-166 that could lead to funding of this trial.
    • 11 Jul 2019 According to a MediciNova media release, the company plans to conduct a single Phase 3 trial. The FDA acknowledged that a single trial can be the basis for marketing approval and the acceptability of a single trial to support drug approval depends on the study results. The FDA agreed that a population of subjects with secondary progressive MS without relapses is an appropriate target population.
    • 06 Feb 2018 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top